Long-Term Outcomes in Patients With iTTP Treated With Caplacizumab and Efficacy of Repeat Caplacizumab Use
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Adding Caplacizumab to Standard-of-Care Therapy for Thrombotic Thrombocytopenic Purpura
- Effectiveness of Caplacizumab vs Standard of Care in Immune Thrombotic Thrombocytopenic Purpura
- Real-World Evidence of Caplacizumab Use in the Management of Acute TTP
- A Regimen With Caplacizumab, Immunosuppression and Plasma Exchange in Immune-Mediated TTP
Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study
J. Thromb. Haemost. 2022 Sep 22;[EPub Ahead of Print], M Scully, J de la Rubia, K Pavenski, A Metjian, P Knöbl, F Peyvandi, S Cataland, P Coppo, JA Kremer Hovinga, J Minkue Mi Edou, R De Passos Sousa, F Callewaert, S Gunawardena, J LinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.